T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects

PURPOSE: Patients with relapsed lymphomas often fail salvage therapies including high-dose chemotherapy and mono-antigen–specific T-cell therapies, highlighting the need for nontoxic, novel treatments. To that end, we clinically tested an autologous T-cell product that targets multiple tumor-associa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Vasileiou, Spyridoula, Lulla, Premal D., Tzannou, Ifigeneia, Watanabe, Ayumi, Kuvalekar, Manik, Callejas, Wendy L., Bilgi, Mrinalini, Wang, Tao, Wu, Mengfen J., Kamble, Rammurti, Ramos, Carlos A., Rouce, Rayne H., Zeng, Zihua, Gee, Adrian P., Grilley, Bambi J., Vera, Juan F., Bollard, Catherine M., Brenner, Malcolm K., Heslop, Helen E., Rooney, Cliona M., Leen, Ann M., Carrum, George
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wolters Kluwer Health 2021
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274795/
https://ncbi.nlm.nih.gov/pubmed/33507803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02224
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia